Sakem Benjamin, Madaliński Kazimierz, Nydegger Urs, Stępień Małgorzata, Godzik Paulina, Kołakowska Agnieszka, Risch Lorenz, Risch Martin, Zakrzewska Karolina, Rosińska Magdalena
Labormedizinisches Zentrum Dr. Risch, Liebefeld, Switzerland.
National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland.
Ann Agric Environ Med. 2016 Sep;23(3):425-31. doi: 10.5604/12321966.1219181.
The aim of the study was to review available data on HCV in Poland and Switzerland, in order to compare the two European countries with respect to epidemiological situation and efficiency of the response systems.
A search of registries, published and grey literature was performed to assemble data on prevalence, rate of detection of new cases, identified risk factors for transmission, mortality due to HCV, prevalence of HCC and the consequent liver transplantations, as well as data on treatment in Poland and Switzerland.
Overall, the prevalence of anti-HCV antibodies was similar, not exceeding 1%. However, the major transmission routes of HCV infections were different: medical procedures in Poland and drug injections in Switzerland. By combining the available information it was also possible to demonstrate important differences in efficiency of the response systems. There was approximately 1 new diagnosis per 100 estimated undiagnosed cases in the population in Poland per year, compared to 6 in Switzerland, and the treatment rate per 100 estimated active infections was 2 and 4, respectively.
Scaling up of the diagnosis and treatment is necessary in both countries; however, the means to achieve this might differ, taking into account the higher concentration of the infections in risk groups in Switzerland than in Poland.
本研究旨在回顾波兰和瑞士关于丙型肝炎病毒（HCV）的现有数据，以便在流行病学情况和应对系统效率方面对这两个欧洲国家进行比较。
检索了登记处、已发表文献和灰色文献，以收集关于流行率、新病例检出率、已确定的传播风险因素、HCV相关死亡率、肝癌患病率及由此导致的肝移植情况的数据，以及波兰和瑞士的治疗数据。
总体而言，抗HCV抗体的流行率相似，均不超过1%。然而，HCV感染的主要传播途径不同：在波兰是医疗程序，在瑞士是药物注射。综合现有信息还可表明，应对系统的效率存在重要差异。波兰每年每100例估计未确诊病例中约有1例新诊断病例，而瑞士为6例，每100例估计的活动性感染的治疗率分别为2例和4例。
两国都有必要扩大诊断和治疗规模；然而，考虑到瑞士高危人群中的感染集中度高于波兰，实现这一目标的方式可能有所不同。
